pirtobrutinib + omeprazole

Pirtobrutinib + omeprazole is a combination of two small molecule drugs. Pirtobrutinib is a highly selective, non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), used to treat relapsed or refractory mantle cell lymphoma and other B-cell malignancies. It is effective even in the presence of Cys481 mutations which commonly render covalent BTK inhibitors ineffective[5][3]. Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by blocking the H+/K+ ATPase in the gastric parietal cells, and is widely used for conditions including peptic ulcers and reflux disease[2]. When administered together, pirtobrutinib can moderately inhibit the CYP2C19 enzyme, increasing omeprazole plasma concentrations, but no clinically significant pharmacokinetic interaction is reported for pirtobrutinib when coadministered with omeprazole[3][4].

Other names

pirtobrutinib + omeprazole